On 22 November 2019, RedHill held an investor and analyst day in New York with the focus on the two new products about to be launched in the US. Talicia and Aemcolo are to be launched imminently (Q419 and Q120 respectively) and could be major products for RedHill. From a commercial perspective, this makes 2020 a potentially transformative year for RedHill, and good sales uptake could be a positive catalyst for the stock. The recent strategic investment of $36.3m by Cosmo Pharmaceuticals means
03 Dec 2019
RedHill Biopharma - 2020 set to be a commercially transformative year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RedHill Biopharma - 2020 set to be a commercially transformative year
- Published:
03 Dec 2019 -
Author:
Dr Jonas Peciulis -
Pages:
8
On 22 November 2019, RedHill held an investor and analyst day in New York with the focus on the two new products about to be launched in the US. Talicia and Aemcolo are to be launched imminently (Q419 and Q120 respectively) and could be major products for RedHill. From a commercial perspective, this makes 2020 a potentially transformative year for RedHill, and good sales uptake could be a positive catalyst for the stock. The recent strategic investment of $36.3m by Cosmo Pharmaceuticals means